A recent review by Brandao and coworkers critically analyzes clinical trials with PI3K inhibitors and suggests KRAS mutations among potential biomarkers for resistance in PIK3CA-mut breast cancer (45, 46). The gene discussed is KRAS; the disease is breast cancer.